BWAY - BrainsWay Ltd. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BWAY

BRAINSWAY LTD.

NASDAQ

$12.15

▼ DOWN 2.80% (-0.35)

KEY STATISTICS

Market Cap$490.29 M

52w High$17.40

52w Low$7.13

Dividend Yield—

Frequency—

P/E30.87

Volume114.28K

Shares Out.39.22M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Hadar Levy

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 17, 2019

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

129

PRICE TARGET

Target High$20.00

Target Low$19.00

Target Median$19.50

Target Consensus$19.50

UPCOMING EARNINGS

DateNov 10, 2026

DayTuesday

Rev. Est.$17.80M

NOV

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2026-03-04	Forward	2:1
2026-03-03	Forward	2:1

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

25.03%

HOLDERS

TOP 8 OF 72 · RANKED BY POSITION SIZE

Valor Management LLC

5.3M sh

$70.64M

Masters Capital Management LLC

1.6M sh

$21.93M

Acadian Asset Management LLC

818.3K sh

$10.86M

Essex Investment Management Co LLC

618.6K sh

$8.22M

Renaissance Technologies LLC

518.4K sh

$6.89M

Cresset Asset Management, LLC

Y.D. More Investments Ltd

272.0K sh

$3.61M

PRICE

$12.15 ▼ DOWN 2.80% (−$0.35)

OVERLAYS

About BrainsWay Ltd.

https://www.brainsway.com ↗

Brainsway Ltd. develops noninvasive neurostimulation treatments using Deep Transcranial Magnetic Stimulation for various mental health and neurological disorders, serving medical professionals worldwide.

INDUSTRY

Medical - Specialties

A PRODUCT BRAINSWAY LTD. IS KNOWN FOR

Deep TMS™ System

A non-invasive medical device utilizing patented H-Coils for deep transcranial magnetic stimulation to treat psychiatric and neurological conditions like depression, OCD, and smoking cessation, with multiple FDA-cleared indications.

COMPETITORS

COMPETITOR

BrainsWay in 2025

SENTIMENT: + POSITIVE

REGULATORY · SEPTEMBER 2025

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Major Depressive Disorder, Slashing Treatment Time

In a pivotal development, BrainsWay announced it had received FDA clearance for an accelerated protocol for its Deep Transcranial Magnetic Stimulation (Deep TMS) system for Major Depressive Disorder (MDD). This new protocol significantly reduces the treatment duration from several weeks of daily sessions to an acute phase of just six treatment days, a move expected to enhance patient access and appeal.

CAPITAL ALLOCATION · JUNE 2025 · IN PROGRESS

BrainsWay Initiates Strategic Program to Acquire Minority Stakes in U.S. Mental Health Providers, Fueling Market Penetration

In a significant strategic pivot, BrainsWay launched a program of making minority-stake investments in various U.S. mental health provider networks throughout 2025. This initiative is designed to provide growth capital to its partners, thereby accelerating patient access to and awareness of BrainsWay's Deep TMS therapy, aiming to secure long-term shareholder value.